Table 10.
—[Section 3.1] Summary of Findings: Should Unfractionated Heparin vs Placebo Be Used for DVT Prevention in Critically Ill Adult Patients?71
| Outcome | No. of Participants (Studies) Follow-up | Quality of the Evidence (GRADE) | Relative Effect (95% CI)c | Anticipated Absolute Effects |
|
| Baseline Risk | Risk Difference With UFH (95% CI) | ||||
| Symptomatic DVT |
1,457 (1 RCT) up to 28 d |
Moderate due to imprecisiona |
RR, 0.89 (0.57-1.41) |
58 per 1,000 |
6 fewer per 1,000 (25 fewer to 24 more) |
| Pulmonary embolus |
1,457 (1 RCT) up to 28 d |
Low due to indirectnessb and imprecisiona |
RR, 0.48 (0.10-2.26) |
42 per 1,000 |
22 fewer per 1,000 (38 fewer to 53 more) |
| Death |
No data |
… |
… |
… |
… |
| Major bleeding | No data | … | … | … | … |
a
We will consider the presence of serious imprecision when there are <300 events in total (events in treatment and control patients) or when CIs include appreciable harms and benefits.
b
Pulmonary embolus baseline risk was obtained from observational studies whereas the relative risk is from RCT (mix of symptomatic and asymptomatic events)
c
RR estimated from a mix of symptomatic and asymptomatic events.